Continuous Fascia Iliaca Block for Acute Hip Fractures
Hip Fractures, Neuromuscular Blockade, Respiratory Morbidity
About this trial
This is an interventional treatment trial for Hip Fractures focused on measuring hip fracture, fascia iliaca block, continuous fascia iliaca block, neuromuscular blockade
Eligibility Criteria
Inclusion Criteria:
- Adults age greater than or equal to 65 years old with acute hip fracture
Exclusion Criteria:
- ASA greater than or equal to 4
- Open fractures
- Other concomitant injuries that may interfere with positioning or pain scores
- Local anesthetic allergy
- Delirium at the time of consent
- Pre-existing cognitive impairment
- Infection at the site of injection for cFIB
- Previous surgery in femoral triangle
- Warfarin or Anti-Xa inhibitor use
- Long-term opioid use
- Intraoperative complications
Sites / Locations
- Royal University Hospital
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Standard Treatment
Continuous fascia iliaca block
Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure. The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter.